Goldfinch Bio Secures $100 Million in Series B Financing
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the closing of an oversubscribed Series B financing, which raised $100 million. The financing was led by Eventide Asset Management, and included new investors Wellington Management Company, Ally Bridge Group, funds…
Details